PROCLAIM

(A Phase 2, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Study to Examine the Effects of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects with Advanced Chronic Congestive Heart Failure)

The PROCLAIM trial is a multicenter phase II trial being conducted in the United States and enrolling approximately 160 patients. The trial is sponsored by Amylin Pharmaceuticals, Inc. The objective of the PROCLAIM trial is to evaluate the safety and tolerability of 2 doses of AC2592 administered by continuous subcutaneous infusion (an insulin-like pump) in subjects with chronic CHF with an NYHA class of III or IV and its effect on oxygen consumption during MVO2 testing. AC2592 is a glucagon-like peptide and is identical to the naturally occurring incretin hormone GLP-1. It is being investigated based on potential actions thought to target the metabolic abnormalities underlying contractile dysfunction and its insulinotropic effects. Eligible patients will receive up to 10 weeks of treatment.

Contant Info Principal Investigator: Ronald P. Karlsberg, MD Study Coordinator: : Maria Thottam, BS Contact number: 310.275.9551

Clinical Trials

Congestive Heart Failure

FUSION II

PROCLAIM

RED HF

Heart Failure Devices

PEGASUS CRT

OPTIMIZER III

Acute Coronary Syndrome

Horizons

Triton – TIMI 38

Coronary Artery Disease

Crescendo

Transcendence PCI

TACT

Carotid Artery Disease

CAPTURE 2

CT Projects

DXV406

DXV301